The estimated Net Worth of Henry J Fuchs is at least $45.6 Milion dollars as of 5 March 2024. Henry Fuchs owns over 35,341 units of Biomarin Pharmaceutical stock worth over $17,983,279 and over the last 16 years he sold BMRN stock worth over $20,552,435. In addition, he makes $7,017,500 as President - Worldwide Research & Development at Biomarin Pharmaceutical.
Henry has made over 75 trades of the Biomarin Pharmaceutical stock since 2010, according to the Form 4 filled with the SEC. Most recently he sold 35,341 units of BMRN stock worth $3,010,346 on 5 March 2024.
The largest trade he's ever made was exercising 126,389 units of Biomarin Pharmaceutical stock on 20 July 2020 worth over $8,337,882. On average, Henry trades about 4,917 units every 32 days since 2009. As of 5 March 2024 he still owns at least 212,117 units of Biomarin Pharmaceutical stock.
You can see the complete history of Henry Fuchs stock trades at the bottom of the page.
Dr. Henry J. Fuchs, M.D., Ph.D., serves as President - Worldwide Research & Development of Biomarin Pharmaceutical Inc. He joined BioMarin in March 2009 and currently serves as our President of Worldwide Research & Development. From December 2009 to October 2016, Dr. Fuchs served as our Executive Vice President and Chief Medical Officer. From March 2009 to December 2009, Dr. Fuchs served as our Senior Vice President and Chief Medical Officer. From September 2005 until December 2008, Dr. Fuchs served as Executive Vice President and Chief Medical Officer for Onyx Pharmaceuticals Inc., a biopharmaceutical company. Dr. Fuchs served as Chief Executive Officer of Ardea Biosciences, Inc. from January 2003 until June 2005. Dr. Fuchs first joined Ardea Biosciences, Inc. as Vice President, Clinical Affairs in October 1996 and was appointed President and Chief Operating Officer in November 2001. From 1987 to 1996, Dr. Fuchs held various positions at Genentech, Inc. where, among other responsibilities, he led the clinical program that resulted in the approval of Pulmozyme, a therapeutic for cystic fibrosis. Dr. Fuchs was also responsible for the Phase III development program that led to the approval of Herceptin to treat metastatic breast cancer. Dr. Fuchs received an M.D. degree from George Washington University and a B.A. degree in biochemical sciences from Harvard University. Dr. Fuchs is currently a Director of Mirati Therapeutics, Inc., a public biopharmaceutical company, and Genomic Health, Inc., a public molecular diagnostics company.
As the President - Worldwide Research & Development of Biomarin Pharmaceutical, the total compensation of Henry Fuchs at Biomarin Pharmaceutical is $7,017,500. There are 1 executives at Biomarin Pharmaceutical getting paid more, with Jean-Jacques Bienaime having the highest compensation of $18,405,900.
Henry Fuchs is 62, he's been the President - Worldwide Research & Development of Biomarin Pharmaceutical since 2016. There are 10 older and 11 younger executives at Biomarin Pharmaceutical. The oldest executive at Biomarin Pharmaceutical Inc. is Alan Lewis, 74, who is the Independent Director.
Henry's mailing address filed with the SEC is C/O BIOMARIN PHARMACEUTICAL INC., 770 LINDARO ST., SAN RAFAEL, CA, 94901.
Over the last 21 years, insiders at Biomarin Pharmaceutical have traded over $153,109,113 worth of Biomarin Pharmaceutical stock and bought 151,118 units worth $2,557,509 . The most active insiders traders include Jean Jacques Bienaime, Mark J Enyedy a Kathryn E Falberg. On average, Biomarin Pharmaceutical executives and independent directors trade stock every 8 days with the average trade being worth of $912,996. The most recent stock trade was executed by Erin Burkhart on 13 August 2024, trading 714 units of BMRN stock currently worth $64,260.
biomarin is a global pharmaceutical company focused on developing first-in-class and best-in-class therapeutics that provide meaningful advances to patients who live with serious and life-threatening rare genetic diseases. we remain steadfast to our original mission—to bring new treatments to market that will make a big impact on small patient populations. these patient populations are mostly children, suffering from diseases so rare, that the entire patient population can number as few as 1,000 people worldwide. these conditions are often inherited, difficult to diagnose, progressively debilitating, have few, if any, treatment options and are usually ignored. time is critical to patients with rare diseases, and we strive to quickly develop important therapies for them. the efficiency and speed of our research, development, manufacturing, and commercial efforts is at the heart of our ability to urgently deliver therapies. our track record of developing and commercializing new treatment
Biomarin Pharmaceutical executives and other stock owners filed with the SEC include: